A Japanese Phase I, Multi-center, Open-label, Study of AUY922 Administered Intravenously on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies.

Trial Profile

A Japanese Phase I, Multi-center, Open-label, Study of AUY922 Administered Intravenously on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2013

At a glance

  • Drugs Luminespib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 04 Apr 2012 Planned number of patients changed from 38 to 31 as reported by ClinicalTrials.gov.
    • 04 Apr 2012 Planned End Date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 09 Aug 2011 Planned end date changed from 1 Jun 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top